

***Plasmodium falciparum*, Strain Dd2<sup>attB</sup>**

**Catalog No. MRA-843**

**Product Description:** *Plasmodium falciparum* (*P. falciparum*), strain Dd2<sup>attB</sup> was generated by integration of the acceptor *attB* site, recognized by the mycobacteriophage Bxb1 integrase during site-specific integration, into the nonessential glutaredoxin-like *cg6* gene located on chromosome 7. *P. falciparum*, strain Dd2 originated in 1980 in Indochina.

**Lot<sup>1</sup>: 63937215**

**Manufacturing Date: 17DEC2015**

TEST	SPECIFICATIONS	RESULTS
Identification by Giemsa Stain Microscopy <sup>2</sup>	Blood-stage parasites present	Blood-stage parasites present
<b>Antimalarial Susceptibility Profile (<i>in vitro</i>)</b> Half-maximal Inhibitory Concentration (IC <sub>50</sub> ) by SYBR green I <sup>®</sup> drug sensitivity assay <sup>3</sup> Chloroquine Artemisinin Quinine Cycloguanil Pyrimethamine Sulfadoxine	Report results Report results Report results Report results Report results Report results	63.5 ± 2.9 nM 11.9 ± 0.8 nM 251.9 ± 34.9 nM 582.8 ± 135.4 nM 26740 ± 1848.6 nM 336900 ± 3107.4 nM
<b>Genotypic Analysis</b> Sequencing of Merozoite Surface Protein 2 (MSP2) gene (860 base pairs) MSP2 PCR amplicon analysis <sup>5</sup>	Consistent with <i>P. falciparum</i> ~ 600-900 base pair amplicon	Consistent with <i>P. falciparum</i> <sup>4</sup> (Figure 1) ~ 900 base pair amplicon
<b>Level of Parasitemia</b> Pre-freeze <sup>6</sup> Post-freeze <sup>7</sup>	Report results > 1%	3.87% 1.51%
<b>Viability (post-freeze)<sup>8</sup></b>	Growth in infected red blood cells	Growth in infected red blood cells
<b>Sterility (21-day incubation)</b> Harpo's HTYE broth <sup>9</sup> , 37°C and 26°C, aerobic Tryptic Soy broth, 37°C and 26°C, aerobic Sabouraud Dextrose broth, 37°C and 26°C, aerobic DMEM with 10% FBS, 37°C, aerobic Sheep Blood agar, 37°C, aerobic Sheep Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic	No growth No growth No growth No growth No growth No growth No growth	No growth No growth No growth No growth No growth No growth No growth
<b>Mycoplasma Contamination</b> DNA Detection by PCR	None detected	None detected

<sup>1</sup>MRA-843 was produced by cultivation of MR-MRA-843 lot 7606700 in fresh human erythrocytes in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 µg/mL hypoxanthine and 2.5 µg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N<sub>2</sub>, 5% CO<sub>2</sub>, 5% O<sub>2</sub>) and monitored for parasitemia daily for 7 days. Every 1 to 2 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture to maintain 2% hematocrit.

<sup>2</sup>Blood-stage malaria parasites (rings, trophozoites, schizonts +/- gametocytes) were examined by microscopic Giemsa-stained blood smears of an *in vitro* human blood culture over 5 days.

<sup>3</sup>A SYBR Green I<sup>®</sup> anti-malarial drug sensitivity assay in 96-well plates was used to determine IC<sub>50</sub> values of an active (> 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I<sup>®</sup>-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In *Methods in Malaria Research Sixth Edition*. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: <https://www.beiresources.org/Publications/MethodsInMalariaResearch.aspx>].

<sup>4</sup>100% sequence identity to GenBank: AASM01000018 (*P. falciparum*, strain Dd2)

<sup>5</sup>Primer sequences and conditions for PCR are available upon request.

<sup>6</sup>Pre-freeze parasitemia was determined after 7 days post infection by microscopic counts of Giemsa-stained blood smears.

<sup>7</sup>Post-freeze parasitemia was determined after 5 days post infection by microscopic counts of Giemsa-stained blood smears.

<sup>8</sup>Viability was confirmed by examination of infected erythrocytes for parasitemia at 5 days post infection.

<sup>9</sup>Atlas, Ronald M. Handbook of Microbiological Media. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

**Figure 1: MRA-843 MSP2 Sequence**

```

CATTGTCTAT TATAAATTTT TTTATTTTTG TTACCTTTAA TATTA AAAAT GAAAGTAAAT ATAGCAACAC ATTCATAAAC
AATGCTTATA ATATGAGTAT AAGGAGAAGT ATGGCAAATG AAGGTTCTAA TACTACTAGT GTAGGTGCAA ATGCTCCAAA
TGCTGATACT ATTGCTAGTG GAAGTCAAAG TAGTACAAAT AGTGCAAGTA CTAGTACTAC TAATAATGGA GAATCACAAA
CTACTACTCC TACCGCTGCT GATACTATTG CTAGTGGAAG TCAAAGGAGT ACAAATAGTG CAAGTACTAG TACTACTAAT
AATGGAGAAT CACAAACTAC TACTCCTACC GCTGCTGATA CTATTGCTAG TGGGAAGTCAA AGGAGTACAA ATAGTGCAAG
TACTAGTACT ACTAATAATG GAGAATCACA AACTACTACT CCTACCGCTG CTGATACCCC TACTGCTACA GAAAGTAATT
CACCTTCACC ACCCATCACT ACTACAGAAA GTTCAAGTTC TGGCAATGCA CCAAATAAAA CAGACGGTAA AGGAGAAGAG
AGTGAAAAAC AAAATGAATT AAATGAATCA ACTGAAGAAG GACCCAAAAGC TCCACAAGAA CCTCAAACGG CAGAAAAATGA
AAATCCTGCT GCACCAGAGA ATAAAGGTAC AGGACAACAT GGACATATGC ATGGTTCTAG AAATAATCAT CCACAAAATA
CTTCTGATAG TCAAAAAGAA TGTACCGATG GTAACAAAGA AAAGTGTGGA GCAGCAACAT CCCTCTTAAA TAACTCTAGT
AATATTGCTT CAATAAATAA ATTTGTTGTT TTAATTTT CAG CAACACTTGT TTTATCTTTT
    
```

**Date:** 10 MAY 2016

**Signature:** 

BEI Resources Authentication

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

